LianBio
LIANY
Other OTC0.17
USD
+0.06
- -
CIK
0001831283
ISIN
US53000N1081
CUSIP
53000N108
Return %
Stock
S&P500
1Y
-56.58
26.57
3Y
-93.40
76.60
5Y
-98.80
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Adam Leo Stone
- Full Time Employees
- 163
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 103 Carnegie Center Drive Princeton NJ United States of America 08540
- IPO Date
- Nov 1, 2021
- CIK
- 0001831283
- Website
- lianbio.com
- Similar Companies
- Business
- LianBio is a biopharmaceutical company specializing in developing and commercializing novel therapeutics for patients in China and other major Asian markets. The company’s core product portfolio targets cardiovascular diseases, oncology, ophthalmology, inflammatory diseases, respiratory conditions, and rare diseases. Its product offerings include precision-based therapies and paradigm-shifting medicines developed through partnerships with global drug developers, which it licenses for late-stage clinical assets primarily focused on high unmet medical needs. LianBio's pipeline includes innovative treatments such as mavacamten for obstructive hypertrophic cardiomyopathy, antiviral therapies for respiratory syncytial virus, and ophthalmic products targeting conditions like Demodex blepharitis. The company operates in China, Taiwan, Hong Kong, Macau, Singapore, and other emerging Asian markets. Founded in 2018 and headquartered in Hong Kong with additional offices in the United States, LianBio leverages strategic alliances to accelerate regulatory submissions and commercialization. Significant recent corporate developments include a strategic collaboration with Pfizer to jointly develop and commercialize transformative pharmaceuticals in Greater China, involving non-dilutive funding and shared commercialization rights. It also formed partnerships with MyoKardia, ReViral, and Tarsus Pharmaceuticals to advance cardiovascular, antiviral, and ophthalmic therapies in its target regions. In late 2024 and 2025, LianBio announced the winding down of its operations, actively pursuing the sale of its remaining pipeline assets after completing a strategic review, marking a major operational shift from prior growth and expansion activities. The company was established by Perceptive Advisors and has built a robust platform focused on importing and adapting late-stage therapies for regional markets based on strong clinical data and scientific validation. Its collaborations with global biopharmaceutical firms enable access to innovative research while addressing localized regulatory and market dynamics. LianBio has prioritized disease relevance and precision therapeutics with a clinical pipeline spanning oncology, cardiovascular, metabolic, and inflammatory diseases, supported by strategic licensing agreements and co-development collaborations. Despite the recent operational wind-down, LianBio’s historical role has been to bridge Western drug innovations to Chinese and Asian healthcare markets through its focused partnership and licensing model.